The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Open accessAbstract
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate Report1 from the Committee of Principal Investigators SUMMARY A double-blind intervention trial was started in 1965 to test the hypothesis that the incidence of ischaemic heart disease in middle-aged men can be reduced by lowering raised serum cholesterol levels.It was carried out in 3 European centres-Edinburgh, Budapest, and Prague.Serum cholesterol was to be lowered by the drug clofibrate (ethyl chlorophenoxyisobutyrate) which was considered to be free from serious side effects.Studies were carried out on 15 745 males, aged 30 to 59 at entry, for an average of 5-3 years, accumu- lating 83 534 years of experience.The treatment group, of about 5000, Group I, was a randomly chosen half of the men in the upper third of the serum cholesterol distribution in some 30 000 volunteers.The comparable control group, Group II, comprised the other 5000 men of the upper third of the cholesterol distribution, and these were given a placebo.A further control group, Group III, of 5000 men, was selected randomly from the lower third of the cholesterol distribution.These numbers were chosen in order to be 90 per cent certain of detecting a 30 per cent reduction in the incidence of ischaemic heart disease should this occur.Subjects with manifest heart or other major disease were excluded from the trial.No attempt was made to correct other 'risk factors' for IHD, but their presence was monitored and considered in the analysis.Investigators and participants in the trial were unaware of the groups to which individual men belonged.A mean reduction of approximately 9 per cent of the initial serum cholesterol levels was achieved in the treatment group (ranging from 7 to 11% in the 3 centres); this was less than the 15 per cent fall expected.In Edinburgh, during treatment, serum triglyceride concentrations in Group I resembled those naturally occurring in Group III.The incidence of IHO was lower by 20 per cent in the clofibrate group compared with the high chol- esterol controls (P <0.05); this fall was confined to non-fatal myocardial infarcts which were reduced by 25 per cent.The incidence offatal heart attacks was similar in the 2 high cholesterol groups and there was no significant difference in the incidence of angina.Group III showed substantially lower rates of ischaemic heart disease.The reduction of myocardial infarction in the clofibrate-treated group was greatest in men with the highest levels, and greatest reduction in serum cholesterol.Men with a substantial reduction of cholesterol concentration, who smoked, and also had above average blood pressure levels showed the most benefit.The numbers of deaths, and crude mortality rates from all causes in the clofibrate-treated group significantly exceeded those in the high cholesterol control group (P < 0.05), though the age-standardised mortality rates did not differ significantly between the 3 groups.The numbers of deaths from 'other 'Prepared by-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Cardiovascular Survey Methods.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-6-1335_2 · Cited by 3,052
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,910
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Estimation of the probability of an event as a function of several independent variables
WALKER, S. H., & DUNCAN, D. B. (1967) · Biometrika · doi:10.1093/biomet/54.1-2.167 · Cited by 1,682
The Electrocardiogram in Population Studies: A Classification System
BLACKBURN, H., KEYS, A., SIMONSON, E., RAUTAHARJU, P., & PUNSAR, S. (1960) · Circulation · doi:10.1161/01.cir.21.6.1160 · Cited by 1,109
ISCHÆMIC HEART-DISEASE IN RELATION TO FASTING VALUES OF PLASMA TRIGLYCERIDES AND CHOLESTEROL
Carlson, L., & Böttiger, L. E. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90738-6 · Cited by 752
DAYTON, S., PEARCE, M. L., HASHIMOTO, S., DIXON, W. J., & TOMIYASU, U. (1969) · Circulation · doi:10.1161/01.cir.40.1s2.ii-1 · Cited by 595
Analysis of Survival Data under the Proportional Hazards Model
Breslow, N. E. (1975) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402659 · Cited by 590
Cited by
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Sick individuals and sick populations
Rose, G. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.3.427 · Cited by 3,736
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Strategy of prevention: lessons from cardiovascular disease.
Rose, G. (1981) · BMJ · doi:10.1136/bmj.282.6279.1847 · Cited by 1,302
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Epidemiology of coronary heart disease: The Framingham study
Castelli, W. P. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90952-5 · Cited by 1,046
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study
Manninen, V. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410050061031 · Cited by 957
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Reddy, J. K., Lalvvai, N. D., & Farber, E. (1983) · CRC Critical Reviews in Toxicology · doi:10.3109/10408448309029317 · Cited by 879
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 796
Neaton, J. D. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400130082009 · Cited by 784
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 758
Hulley, S. B., Rosenman, R. H., Bawol, R. D., & Brand, R. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006193022503 · Cited by 702
Carlson, L. A., & ROSENHAMER, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 677
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
Levine, G. N., Keaney, J. F., & Vita, J. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320807 · Cited by 672
Brensike, J. F., Levy, R. I., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., Battaglini, J. W., & Moriarty, D. J. (1984) · Circulation · doi:10.1161/01.cir.69.2.313 · Cited by 668
Leger, A. S. S., Cochrane, A. L., & Moore, F. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92765-x · Cited by 663
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 647
PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance
Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., et al. (2003) · Critical Reviews in Toxicology · doi:10.1080/713608372 · Cited by 611
Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
Grundy, S. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00033-2 · Cited by 525
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450010075034 · Cited by 428
The Value of Lowering Cholesterol after Myocardial Infarction
Rossouw, J. E., Lewis, B., & Rifkind, B. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010183231606 · Cited by 410
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Number needed to screen: development of a statistic for disease screening
Rembold, C. M. (1998) · BMJ · doi:10.1136/bmj.317.7154.307 · Cited by 383
Andrade, S. E., Walker, A. M., Gottlieb, L. K., Hollenberg, N. K., Testa, M. A., Saperia, G. M., & Platt, R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321703 · Cited by 379
Goldman, L. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460090093039 · Cited by 357
Should there be a moratorium on the use of cholesterol lowering drugs?
Davey Smith, G., & Pekkanen, J. (1992) · BMJ · doi:10.1136/bmj.304.6824.431 · Cited by 333
Willett, W. C., & MacMahon, B. (1984) · New England Journal of Medicine · doi:10.1056/nejm198403083101006 · Cited by 328
Cholesterol lowering trials in coronary heart disease: Frequency of citation and outcome.
Ravnskov, U. (1992) · BMJ · doi:10.1136/bmj.305.6844.15 · Cited by 313
Ashby, J., Brady, A., Elcombe, C. R., Elliott, B. M., Ishmael, J., Odum, J., Tugwood, J. D., Kettle, S., & Purchase, I. F. H. (1994) · Human & Experimental Toxicology · doi:10.1177/096032719401300201 · Cited by 313
Marston, N. A., Giugliano, R. P., Im, K., Silverman, M. G., O’Donoghue, M. L., Wiviott, S. D., Ference, B. A., & Sabatine, M. S. (2019) · Circulation · doi:10.1161/circulationaha.119.041998 · Cited by 301
Faed, E. M. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033562 · Cited by 299
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Cholesterol Reduction Yields Clinical Benefit: A New Look at Old Data
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1995) · Circulation · doi:10.1161/01.cir.91.8.2274 · Cited by 272
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Santos, R. D. (2001) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2001001500001 · Cited by 273
Drugs Five Years Later: Desmopressin
RICHARDSON, D. W., & ROBINSON, A. G. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-2-228 · Cited by 272
Hepatic peroxisome proliferation in rodents and its significance for humans
Bentley, P., Calder, I., Elcombe, C., Grasso, P., Stringer, D., & Wiegand, H.-J. (1993) · Food and Chemical Toxicology · doi:10.1016/0278-6915(93)90225-n · Cited by 271
van Raalte, D. H., Li, M., Pritchard, P. H., & Wasan, K. M. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041444.06122.8d · Cited by 269
Dietary fiber and coronary heart disease
Anderson, J. W., Deakins, D. A., Floore, T. L., Smith, B. M., & Whitis, S. E. (1990) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408399009527518 · Cited by 268
Soft-tissue sarcomas and exposure to chemical substances: a case-referent study.
Eriksson, M., Hardell, L., Berg, N. O., Moller, T., & Axelson, O. (1981) · Occupational and Environmental Medicine · doi:10.1136/oem.38.1.27 · Cited by 267
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
Antithrombotic agents in coronary artery disease
Resnekov, L., Chediak, J., Hirsh, J., & Lewis, H. D. (1989) · Chest · doi:10.1378/chest.95.2.52s · Cited by 263
Matsuzaki, M., Kita, T., Mabuchi, H., Matsuzawa, Y., Nakaya, N., Oikawa, S., Saito, Y., Sasaki, J., Shimamoto, K., Itakura, H., et al. (2002) · Circulation Journal · doi:10.1253/circj.66.1087 · Cited by 260
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Pignone, M. (2000) · BMJ · doi:10.1136/bmj.321.7267.983 · Cited by 259
Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)
Miller, D. B., & Spence, J. D. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834020-00003 · Cited by 259
Woolf, S. (1990) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(90)90073-x · Cited by 259
DUFFIELD, R. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92527-8 · Cited by 252
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181
The PPARα-Dependent Rodent Liver Tumor Response Is Not Relevant to Humans: Addressing Misconceptions
Corton, J. C., Peters, J. M., & Klaunig, J. E. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2094-7 · Cited by 175
Balling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.610 · Cited by 175
Fibrates for primary prevention of cardiovascular disease events
Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753.pub2 · Cited by 147
The Kyushu Lipid Intervention Study Group (2000) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.7.110 · Cited by 67
Riaz, H., Khan, S. U., Rahman, H., Shah, N. P., Kaluski, E., Lincoff, A. M., & Nissen, S. E. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318816495 · Cited by 61
Cholesterol Reduction and Clinical Benefit: Are There Limits to Our Expectations?
Fager, G., & Wiklund, O. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.12.3527 · Cited by 62
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Kim, K. A., Kim, N. J., & Choo, E. H. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad331 · Cited by 36
Program, T. L. R. C. (1983) · Journal of Chronic Diseases · doi:10.1016/0021-9681(83)90138-8 · Cited by 29
Blackburn, H. (1989) · Annals of Medicine · doi:10.3109/07853898909149926 · Cited by 11
Novel strategies for managing dyslipidemia: treatment beyond statins
Ling, H., Burns, T. L., & Hilleman, D. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2612 · Cited by 10
Metadata
- Venue
- Heart
- Publisher
- BMJ
- Published
- 1978-10-01
- Volume
- 40
- Issue
- 10
- Pages
- 1069-1118
- ISSN
- 1355-6037 (ISSN-L)
- OpenAlex
- W2615845755
- Cited by
- 1,046
- References
- 32
- FWCI
- 91.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.